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Review article
Montelukast, a leukotriene receptor antagonist, was launched 
20 years ago in Korea. It is recommended as an alternative 
treatment for asthma in children with mild persistent symptoms 
or as an add-on treatment to existing low-dose inhaled corti-
costeroids (ICSs) in children who require additional treatment. 
However, in the real-world setting, many doctors and patients 
prefer montelukast over ICSs despite their lower efficacy. Al-
though montelukast is considered to be a safe drug, there are 
concerns regarding adverse drug reactions, including the rare 
occurrence of Churg-Strauss syndrome and, despite insufficient 
data, the possibility of neuropsychiatric events such as anxiety, 
depression, sleep disturbance, and suicidality. This review identi-
fied that montelukast has significantly contributed to asthma 
control over the past 20 years in Korea and has been critical for 
reducing asthma severity, especially early wheezing and disease 
control. Our findings suggest that the effects of montelukast 
treatment can be monitored by measuring serum eosinophil-
derived neurotoxin levels.
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Key message
Although the efficacy of montelukast is inferior to that of ICS, 
both physicians and parents prefer montelukast to ICSs. 
EDN may be a useful biomarker for the treatment and moni-
toring of preschool children with asthma. 
The US FDA requires boxed warning about serious neuropsy-
chiatric events of montelukast, therefore, physicians should con-
sider the benefits and risks of montelukast before prescribing it. 
Introduction
Leukotrienes (LTs) are substances secreted by leukocytes that 
have three conjugated double bonds. Researchers have known 
since 1930 that the sputum of asthmatic patients contains a sub-
stance that causes smooth muscle constriction.1) This substance 
was termed slow-reacting substance of anaphylaxis (SRS-A) 
since it causes slow contractions of the smooth muscle after being 
released from sensitized lungs during an anaphylactic reaction.2) 
In the late 1970s, SRS-A was shown to be part of the LT family.3) In 
1980, the LTs C4 and D4 (LTC4 and LTD4, respectively) repor-
tedly showed remarkable contractile activity on isolated human 
bronchi.4) Thereafter, the number of studies on LTs as candidate 
asthma treatments increased. LT modifiers include LT receptor 
antagonists (LTRAs) and 5-lipoxygenase (5-LO) inhibitors. LTRAs 
include zafirlukast, montelukast, and pranlukast, while 5-LO 
inhibitors include zileuton. Of these, montelukast is the most 
widely prescribed and studied worldwide. This review describes 
the synthesis and function of LTs and the effects and safety of 
montelukast, a representative LTRA.
Biosynthesis of LTs
The biosynthesis of LTs begins in the cell membrane. When 
a variety of biological stimuli occur, phospholipids in the 
cell membrane are metabolized to arachidonic acid (AA) by 
phospholipase A2. AA is converted to prostaglandin (PG) or 
thromboxane by cyclooxygenase or to 5-hydroperoxyeicosate-
traenoic acid (5-HPETE) by 5-LO and 5-LO-activating protein 
(FLAP). Next, 5-HPETE is transformed into 5-hydroxyeicosate-
traenoic acid (5-HETE) or LTA4. LTA4 is then converted to 
LTB4 by LTA4 hydrolase or binds to reduced glutathione using 
LTC4 synthase to form LTC4. LTC4 is converted to LTD4 
by the removal of glutamic acid by α-glutamyl transpeptidase, 
while LTD4 is converted to LTE4 by the removal of glycine by 
dipeptidase. LTC4, LTD4, and LTE4 are called cysteinyl LTs 
(cysLTs) because they contain cysteine.
Role of LTs in the airway
CysLTs have several effects that contribute to the pathogenesis 
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macrophages, eosinophils, basophils, mast cells, epithelial cells, 
fibrocytes, and endothelial cells.13) The binding affinity for cysLT1 
among cysLTs is the highest in LTD4, followed by LTC4 and LTE, 
which shows very weak binding affinity. The binding affinity for 
cysLT2 is similar in LTD4 and LTC4, while that of LTE4 is weak.13-
15) There is no currently available selective cysLT2 antagonist. 
Commercialized LTRAs, such as montelukast, pranlukast, and 
zafirlukast, act selectively on cysLT1 but not cysLT2. Therefore, 
asthma-associated cysLT activity is thought to involve cysLT1.
Clinical use of montelukast in children with 
asthma
1. Current pediatric asthma management guidelines
The current guidelines state that low-dose inhaled corticoste-
roids (ICS) may be used primarily in children of all ages when 
maintenance therapy is needed and that LTRAs should be ad-
ministered as an alternative treatment. If step-up treatment is 
required, the prescription of moderate-dose ICS or LTRAs in 
combination with low-dose ICS is recommended for children 
aged <6 years. For children aged ≥6 years, the use of low-dose 
of asthma. First, they act as potent bronchoconstrictors in hu-
mans. When the lung tissues of asthmatic patients were stimulat-
ed with specific allergens, cysLT secretions increased and the 
cysLT amounts released were correlated with bronchial smooth 
muscle contractions.5) When LTD4 was inhaled in vivo, the 
bronchial smooth muscle contracted and lung function was de-
creased regardless of asthma status.6) CysLTs up-regulate the 
expression of endothelial adhesion molecules, act as a powerful 
chemoattractant for eosinophils, and reduce eosinophil apopto-
sis, thus leading to eosinophilic inflammation.7) CysLTs also in-
crease vascular leakage, which in turn exacerbates mucosal ede-
ma, increases mucus production and secretion by goblet cells, and 
decreases mucociliary clearance.8-10) Furthermore, cysLTs con -
tribute to airway remodeling, promote smooth muscle cell pro-
liferation, and increase collagen deposition in the airways (Fig. 1). 
11,12)
CysLT receptors are classified as cysLT1 and cysLT2. Montelu-
kast, zafirlukast, and pranlukast are selective cysLT1 antagonists. 
CysLT1 is expressed by macrophages, dendritic cells, eosinophils, 
basophils, mast cells, B cells, CD4+ T cells, hematopoietic pro-
genitor cells, epithelial cells, airway smooth muscle cells, fibro-


































Fig. 1. Biosynthesis and role of leukotrienes. 5-LO, 5-lipoxygenase; FLAP, 5-LO-activating protein; 5-HPETE, 
5-hydroperoxyeicosatetraenoic acid; 5-HETE, 5-hydroxyeicosatetraenoic acid; LT, leukotriene; GTP, glutamyl 
transpeptidase.
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ICS in combination with long-acting beta-2 agonists is recom-
mended, while high- or low-dose ICS with LTRAs are recom-
mended as alternative treatments.16,17)
2. Comparison with ICSs
A Cochrane review that analyzed 19 pediatric randomized 
controlled trials (RCTs) to compare the efficacy of montelukast 
to that of ICS revealed the superior efficacy of the latter.18) A 
meta-analysis of RCTs in preschoolers with asthma or recurrent 
wheezing also reported that daily ICS use was more effective 
than montelukast treatment.19) However, several studies showed 
different outcomes in real-life environments since the actual ef-
fects of a medication are determined by both medication efficacy 
and patient compliance. Ducharme et al.20) examined the real-life 
effectiveness of montelukast versus ICS in children with mild or 
moderate asthma. Physicians prescribed medication for 62% of 
the follow-up period when prescribing ICS versus 97% of follow-
up when prescribing montelukast. Patients purchased 51% versus 
74% of the prescribed ICS and montelukast at pharmacies, 
respectively. As a result, children who were prescribed ICS used 
the medication for 24% of the follow-up period, while those who 
were prescribed montelukast used the medication for 38% of the 
follow-up period. There was no intergroup difference in the rates 
of oral corticosteroid use or emergency room visits, but the ICS 
prescription groups were the more frequently admitted and more 
frequently required rescue beta-2 agonists.20) According to a study 
analyzing the Korean National Health Insurance claim database 
from 2010 to 2014, LTRAs including montelukast were the most 
prescribed in children of all ages with asthma. The rate of ICS 
prescriptions for asthmatic patients aged ≥6 years was <15%.21) 
These results suggest that Korean pediatricians prefer to prescribe 
montelukast rather than ICS. In a recent survey of 1,838 pediatric 
patients currently receiving treatment for asthma in Korea and 
their parents, 38% of patients receiving inhaled treatment and 
50% of those receiving LTRAs were taking the treatment as 
prescribed. Furthermore, 70% of LTRA users versus only 34% of 
inhaler users felt that their treatment modality was easy to use.22)
A randomized study comparing responses to fluticasone inhaler 
and montelukast treatment in school-aged children with mild to 
moderate asthma defined a response as a ≥7.5% improvement 
in forced expiratory volume in 1 second (FEV1), and showed 
that 5% of the children responded to montelukast only, 23% 
responded to fluticasone only, 17% responded to both medica-
tions, and 55% responded to neither medication. Predictors of 
good response to fluticasone only were lower pulmonary func­
tion and provocative concentration causing a 20% drop in FEV1, 
and higher FeNO levels, total eosinophil counts, serum eosino-
phil cationic protein (ECP), and total immunoglobulin E. Con-
versely, predictors of good response to montelukast were lower 
age and short duration of asthma.23)
In summary, although the efficacy of montelukast is inferior 
to that of ICSs and asthma management guidelines recommend 
that ICSs be prescribed primarily when starting maintenance 
therapy, both physicians and patients prefer montelukast to ICSs. 
In addition, some patients respond better to montelukast than 
to ICS, but additional studies are needed to determine which 
patients will respond better.
3. Preschool children with asthma or recurrent wheezing
There are currently no specific tools or biomarkers available to 
diagnose asthma in preschool children. Therefore, it is important 
for physicians to recognize the various patterns of recurrent 
wheez ing in this population. The proposed phenotypes of recu-
rrent wheezing in early childhood are as follows: transient wheez-
ing, nonatopic wheezing, persistent asthma, and severe intermit-
tent wheezing.24,25) This classification is helpful in under standing 
childhood wheezing but is difficult to use clinically. Wheezing may 
be classified as an “episodic (viral) wheeze” (EVW) or “multiple-
trigger wheeze” (MTW).26) An EVW is defined as wheezing 
during discrete time periods, often in association with the clinical 
evidence of a viral cold, with an absence of wheezing between 
episodes. An MTW is defined as wheezing that shows discrete 
exacerbations but also symptoms between episodes.
A recent meta-analysis reported on the effects of montelukast 
treatment for the prevention of post-bronchiolitis wheezing.27) 
The authors concluded that montelukast reduced the frequency of 
recurrent wheezing but did not reduce the incidence of recurrent 
wheezing, corticosteroid use, or number of symptom-free days 
in post-bronchiolitis infants; therefore, it was not appropriate for 
clinical use. However, in an RCT of post-bronchiolitis patients 
treated with montelukast for 3 months and followed up for 12 
months, the serum eosinophil-derived neurotoxin (EDN) levels 
were significantly decreased and cumulative recurrent wheezing 
episodes were significantly decreased in the montelukast-treated 
group.28)
A Cochrane review of the effects of LTRA against EVW in 
preschool children reported that LTRA maintenance or intermit-
tent therapy did not reduce the number of children experi encing 
one or more episodes requiring rescue medicine, emergency room 
visits, or hospital admissions.29,30) However, the authors suggested 
that certain subgroups may respond to LTRA since children with 
EVW did not show homogeneous phenotypes and that they 
should be prescribed montelukast as a therapeutic trial and con-
tinue maintenance therapy if they respond well. The European 
Respiratory Society (ERS) recommended that, montelukast 
should be the first choice for daily maintenance therapy in children 
with EVW, while ICSs should be the first choice of maintenance 
therapy in children with MTW. However, the ERS highlighted that 
it is difficult to distinguish EVW from MTW in some children.31) 
A recent meta-analysis of the effects of montelukast against both 
EVW and MTW in preschool children reported that montelukast 
was ineffective in preschool children with recurrent wheezing. 
The authors suggested that further studies should be conducted 
to investigate how to easily identify montelukast responders in 
clinical settings.32)
EDN may be a useful biomarker for the treatment and moni-
toring of preschool children with asthma or recurrent wheezing. 
33,34) EDN is one of four major proteins secreted by activated 
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eosinophils together with ECP, major basic protein, and eosino-
phil peroxidase. Unlike the other three, EDN has an isoelectronic 
point of 8.3, which is close to neutral; therefore, it is possible to 
measure accurately and reproducibly in the blood.35) In a previous 
study, we compared the concentrations of serum EDN to asthma 
symptom scores in preschool children.36) Serum EDN levels were 
the highest in children with acute asthma, followed by those with 
stable asthma and those in the control group, and the differences 
among the three groups were significant. Another study suggested 
that serum EDN levels 3 months after respiratory syncytial virus 
bronchiolitis were predictive of recurrent wheezing within 12 
months. The serum EDN concentration cutoff value for pre-
dicting wheezing recurrence was 53 ng/mL (positive predictive 
value, 57%; negative predictive value, 76%; sensitivity, 72%; and 
specificity, 62%). The normal range of serum EDN concentration 
was 13–45 ng/mL.28) Predictive value of EDN levels for asthma 
was based on clinical performance result. Using 44.2 ng/mL 
(median+1SD) as the cut off for an elevated EDN level compared 
to those found in Controls, the sensitivity was 81.3%, the speci-
ficity was 87.1%, the positive predictive value (PPV) of EDN level 
for asthma 90.7 %, and the negative predictive value (NPV) was 
75.0%.35) Another recent study compared the effects of mon-
telukast and 0.5-mg budesonide inhalation suspension therapy 
for 12 weeks in symptomatic preschool children with asthma 
and serum EDN levels ≥53 ng/mL.37) During the study period, 
asthma control days increased in both groups and there was no 
significant intergroup difference. However, serum EDN levels 
were significantly decreased only in the montelukast group. 
Therefore, based on several years of EDN-related research, we 
recommend starting maintenance therapy with montelukast 
when the EDN concentration is ≥53 ng/mL (1 SD of normal) 
and stopping when it decreases to <45 ng/mL (Fig. 2).
Current clinical practice guidelines recommended controller 
therapy for children experiencing daytime asthma symptoms 
more than once a week, with activity limitations, who require 
the use of a reliever more than once a week, or who have any 
nighttime symptoms.16) However, a recent study compared the 
efficacy of montelukast maintenance therapy and as-needed β2-
agonist therapy for 48 weeks in preschool children experiencing 
asthma symptoms more than once a month but less than once a 
week.38) During the study, 28% of the montelukast group and 
50% of the no-controller group experienced asthma exacer-
bations; 21% and 41% of the children, respectively, required 
increased treatment. Therefore, montelukast use should be con-
sidered as maintenance therapy in preschool children with inter-
mittent asthma (Table 1).
The efficacy of LTRAs combined with antihistamines is often 
mentioned in clinical journals and guidelines. The combination 
of montelukast and 2nd-generation antihistamines may protect 
against seasonal decreases in lung function in patients with al-
lergic rhinitis. Furthermore, LTRAs may be more effective at 
treating allergic rhinitis when combined with antihistamines since 
the agents have different efficacies. Recently, one such compound 
was developed and marketed for children in Korea.39)
Safety profile
The most commonly reported clinical adverse events of mon-
telukast treatment were fever, upper respiratory infection, and 
asthma exacerbation. However, montelukast is considered a safe 
drug because its reported incidence of adverse drug reactions 
(ADRs) was similar to that of the control group.40)
Major concerns related to montelukast-associated ADRs 
included the occurrence of Churg-Strauss syndrome (CSS) and 
the possible association between LTRA and suicidality. A case-
crossover study of 78 patients with CSS reported that the use 
of montelukast was associated with a 4.5-fold increased risk of 




























Fig. 2. Monitoring of leukotriene receptor antagonist effects. EDN, 
eosinophil-derived neurotoxin.
Table 1. Clinical effects of montelukast in preschool children




Decrease in wheezing frequency after RSV 
infection. No short-acting effects on reducing 
wheezing episodes requiring rescue medicine, 
ER visit, and hospital admission
Recommended as a therapeutic trial
Multiple-trigger 
wheeze
Montelukast responder’ phenotype exists. 
Studying how to easily identify these pheno-
types
Recommended as an alternative treatment of 
low-dose ICS
Asthma
Intermittent Effective on reducing asthma exacerbation
Recommended as an additional treatment of 
short-acting beta agonist
Persistent Effective on reducing serum EDN concentra-
tions.
Less effective than daily ICS for improving asth-
ma symptoms and preventing exacerbation
Recommended as an alternative treatment of 
low-dose ICS
RSV. respiratory syncytial virus; ER, emergency room; ICS, inhalation 
corticosteroids; EDN, eosinophil-derived neurotoxin.
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granulomatosis with polyangiitis, is a rare autoimmune disorder 
that causes vasculitis in patients with a history of asthma or allergic 
rhinitis. Treatment for CSS includes glucocorticoids (such as 
prednisolone) and other immunosuppressive drugs. Therefore, 
montelukast is simply a confounding factor, and the withdrawal 
of steroid use may be associated with the development of CSS 
symptoms.
The United States Food and Drug Administration issued a 
warning in 2008 regarding the possible association between 
montelukast use and suicidality; moreover, in 2020, it announced 
that the drug requires a boxed warning about mental health side 
effects because many other antiallergy medicines can be pre-
scribed instead and many health care professionals and patients/
caregivers are not aware of the risk of mental health side effects. 
Many studies that have analyzed published case reports or data-
bases of adverse drug response reporting systems suggested that 
montelukast use is associated with neuropsychiatric events such 
as anxiety, sleep disturbance, depression, and suicidality.42-44) A 
recent nested case-control study of 898 cases and 3,497 con trols 
from a cohort of children with asthma aged 5–18 years in 2004–
2015 reported that children who were prescribed montelukast 
had increased odds (2 times) of experiencing a neuropsychiatric 
event.45) However, 2 recent systematic reviews on this issue 
reported that the association between neuropsychiatric events 
and montelukast use was reported by studies using pharma-
covigilance databases and not by observational or cohort studies. 
46,47) A study assessing a cohort of 670 adults with allergic rhinitis 
in Spain reported that the severity of allergic rhinitis was related to 
a worse quality of life, sleep disturbances, depression, and anxiety. 
48) One study investigated the association between montelukast 
and antidepressant use and reported that montelukast initiation 
was weakly associated with antidepressant prescription. How-
ever, the study concluded that antidepressant use, not mon-
telukast use, may be correlated with asthma severity.49) A study 
using an animal allergic rhinitis model reported that allergic 
rhinitis was associated with the induction of an inflammatory 
response in the hippocampus and that it may trigger associated 
neuropsychiatric events.50) These findings do not guarantee the 
safety of montelukast; therefore, clinicians should consider the 
benefits and risks of montelukast before prescribing it.
Conclusion
The efficacy of montelukast for pediatric asthma is inferior to 
that of ICSs. Nonetheless, montelukast has several advantages. 
First, patients using ICS must use the correct inhalation technique, 
whereas no special skills are required to administer montelukast. 
Second, both patients and prescribing physicians prefer to use 
a drug that is administered only once a day. Third, there is no 
impact on growth, unlike the use of ICSs, which can potentially 
impair a child’s growth.51)
Montelukast maintenance therapy is primarily recommended 
for asthmatic children who experience symptoms more than 
once a month but less than once a week and is recommended as 
an alternative method for children with step 2 asthma.
Serum EDN can be used as a biomarker to monitor the effectiv-
eness of pediatric asthma treatment. We recommend starting 
maintenance therapy with montelukast when the EDN level is 
≥53 ng/mL and stopping when the EDN level decreases to <45 
ng/mL. However, additional studies are needed to determine the 
validity of these recommendations.
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